{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:26Z","timestamp":1789450466436,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T00:00:00Z","timestamp":1635292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Jill and John Svoboda; The Rizzo Family Foundation"},{"DOI":"10.13039\/100000057","name":"U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007281"],"award-info":[{"award-number":["T32GM007281"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"name":"AbbVie-University of Chicago Collaborative; The Comer Developmental Board; Jill and John Svoboda; The Rizzo Family Foundation; Donald and Catherine Kleinmuntz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>BH3 mimetics are increasingly used as anti-cancer therapeutics either alone or in conjunction with other chemotherapies. However, mounting evidence has also demonstrated that BH3 mimetics modulate varied amounts of apoptotic signaling in healthy immune populations. In order to maximize their clinical potential, it will be essential to understand how BH3 mimetics affect discrete immune populations and to determine how BH3 mimetic pressure causes immune system adaptation. Here we focus on the BCL-2 specific inhibitor venetoclax (ABT-199) and its effects following short-term and long-term BCL-2 blockade on T cell subsets. Seven day \u201cshort-term\u201d ex vivo and in vivo BCL-2 inhibition led to divergent cell death sensitivity patterns in CD8<jats:sup>+<\/jats:sup> T cells, CD4<jats:sup>+<\/jats:sup> T cells, and Tregs resulting in shifting of global T cell populations towards a more memory T cell state with increased expression of BCL-2, BCL-X<jats:sub>L<\/jats:sub>, and MCL-1. However, twenty-eight day \u201clong-term\u201d BCL-2 blockade following T cell-depleted bone marrow transplantation did not lead to changes in the global T cell landscape. Despite the lack of changes in T cell proportions, animals treated with venetoclax developed CD8<jats:sup>+<\/jats:sup> and CD4<jats:sup>+<\/jats:sup> T cells with high levels of BCL-2 and were more resistant to apoptotic stimuli following expansion post-transplant. Further, we demonstrate through RNA profiling that T cells adapt while under BCL-2 blockade post-transplant and develop a more activated genotype. Taken together, these data emphasize the importance of evaluating how BH3 mimetics affect the immune system in different treatment modalities and disease contexts and suggest that venetoclax should be further explored as an immunomodulatory compound.<\/jats:p>","DOI":"10.1038\/s41419-021-04285-4","type":"journal-article","created":{"date-parts":[[2021,10,27]],"date-time":"2021-10-27T06:02:46Z","timestamp":1635314566000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells"],"prefix":"10.1038","volume":"12","author":[{"given":"Lindsey M.","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina M.","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9233-5128","authenticated-orcid":false,"given":"David B.","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika T.","family":"Thomas-Toth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Blazar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8260-3598","authenticated-orcid":false,"given":"Megan E.","family":"McNerney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Leverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6776-4695","authenticated-orcid":false,"given":"James L.","family":"LaBelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,27]]},"reference":[{"key":"4285_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"4285_CR2","doi-asserted-by":"publisher","first-page":"2661","DOI":"10.1111\/febs.13472","volume":"283","author":"JT Opferman","year":"2016","unstructured":"Opferman JT. Attacking cancer\u2019s Achilles heel: antagonism of anti-apoptotic BCL-2 family members. FEBS J. 2016;283:2661\u201375.","journal-title":"FEBS J"},{"key":"4285_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/sj.gene.6364173","volume":"6","author":"AR Abbas","year":"2005","unstructured":"Abbas AR, Baldwin D, Ma Y, Ouyang W, Gurney A, Martin F, et al. Immune response in silico (IRIS): immune-specific genes identified from a compendium of microarray expression data. Genes Immun. 2005;6:319\u201331.","journal-title":"Genes Immun"},{"key":"4285_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","volume":"11","author":"FJ Kohlhapp","year":"2020","unstructured":"Kohlhapp FJ, Haribhai D, Mathew R, Duggan R, Ellis PA, Wang R, et al. Venetoclax increases intra-tumoral effector T cells and anti-tumor efficacy in combination with immune checkpoint blockade. Cancer Discov. 2020;11:68\u201379.","journal-title":"Cancer Discov"},{"key":"4285_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57000-x","volume":"10","author":"L Rohner","year":"2020","unstructured":"Rohner L, Reinhart R, Iype J, Bachmann S, Kaufmann T, Fux M. Impact of BH3-mimetics on human and mouse blood leukocytes: a comparative study. Sci Rep. 2020;10:222.","journal-title":"Sci Rep"},{"key":"4285_CR6","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/leu.2014.1","volume":"28","author":"SL Khaw","year":"2014","unstructured":"Khaw SL, Merino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014;28:1207\u201315.","journal-title":"Leukemia"},{"key":"4285_CR7","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1084\/jem.20070618","volume":"204","author":"S Wojciechowski","year":"2007","unstructured":"Wojciechowski S, Tripathi P, Bourdeau T, Acero L, Grimes HL, Katz JD, et al. Bim\/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med. 2007;204:1665\u201375.","journal-title":"J Exp Med"},{"key":"4285_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fimmu.2016.00073","volume":"7","author":"SS Gabriel","year":"2016","unstructured":"Gabriel SS, Bon N, Chen J, Wekerle T, Bushell A, Fehr T, et al. Distinctive expression of Bcl-2 factors in regulatory T cells determines a pharmacological target to induce immunological tolerance. Front Immunol. 2016;7:73.","journal-title":"Front Immunol"},{"key":"4285_CR9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fped.2016.00135","volume":"4","author":"LM Ludwig","year":"2016","unstructured":"Ludwig LM, Nassin ML, Hadji A, LaBelle JL. Killing two cells with one stone: pharmacologic BCL-2 family targeting for cancer cell death and immune modulation. Front Pediatr. 2016;4:135.","journal-title":"Front Pediatr"},{"key":"4285_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/nyas.12045","volume":"1285","author":"TT Renault","year":"2013","unstructured":"Renault TT, Chipuk JE. Getting away with murder: how does the BCL-2 family of proteins kill with immunity? Ann N. Y Acad Sci. 2013;1285:59\u201379.","journal-title":"Ann N. Y Acad Sci"},{"key":"4285_CR11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10495-020-01593-6","volume":"25","author":"LM Ludwig","year":"2020","unstructured":"Ludwig LM, Roach LE, Katz SG, LaBelle JL. Loss of BIM in T cells results in BCL-2 family BH3-member compensation but incomplete cell death sensitivity normalization. Apoptosis. 2020;25:247\u201360.","journal-title":"Apoptosis"},{"key":"4285_CR12","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.4049\/jimmunol.178.5.2961","volume":"178","author":"D Haribhai","year":"2007","unstructured":"Haribhai D, Lin W, Relland LM, Truong N, Williams CB, Chatila TA. Regulatory T cells dynamically control the primary immune response to foreign antigen. J Immunol. 2007;178:2961\u201372.","journal-title":"J Immunol"},{"key":"4285_CR13","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1172\/JCI46231","volume":"122","author":"JL LaBelle","year":"2012","unstructured":"LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, et al. A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest. 2012;122:2018\u201331.","journal-title":"J Clin Invest"},{"key":"4285_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-8861-7_5","volume":"1877","author":"LM Ludwig","year":"2019","unstructured":"Ludwig LM, Maxcy KL, LaBelle JL. Flow cytometry-based detection and analysis of BCL-2 family proteins and mitochondrial outer membrane permeabilization (MOMP). Methods Mol Biol. 2019;1877:77\u201391.","journal-title":"Methods Mol Biol"},{"key":"4285_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/laban0511-155","volume":"40","author":"T Yardeni","year":"2011","unstructured":"Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. Retro-orbital injections in mice. Lab Anim. 2011;40:155\u201360.","journal-title":"Lab Anim"},{"key":"4285_CR16","doi-asserted-by":"publisher","first-page":"E1288","DOI":"10.1073\/pnas.1411848112","volume":"112","author":"AC Faber","year":"2015","unstructured":"Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, et al. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer. Proc Natl Acad Sci USA. 2015;112:E1288\u20131296.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4285_CR17","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","volume":"68","author":"C Tse","year":"2008","unstructured":"Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68:3421\u20138.","journal-title":"Cancer Res"},{"key":"4285_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0076-6879(08)01623-6","volume":"446","author":"K Pitter","year":"2008","unstructured":"Pitter K, Bernal F, Labelle J, Walensky LD. Dissection of the BCL-2 family signaling network with stabilized alpha-helices of BCL-2 domains. Methods Enzymol. 2008;446:387\u2013408.","journal-title":"Methods Enzymol"},{"key":"4285_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139\u201340.","journal-title":"Bioinformatics"},{"key":"4285_CR20","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102:15545\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4285_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/nprot.2008.211","volume":"4","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44\u201357.","journal-title":"Nat Protoc"},{"key":"4285_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/nar\/gkn923","volume":"37","author":"W Huang da","year":"2009","unstructured":"Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37:1\u201313.","journal-title":"Nucleic Acids Res"},{"key":"4285_CR23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1038\/cdd.2017.30","volume":"24","author":"EM Carrington","year":"2017","unstructured":"Carrington EM, Zhan Y, Brady JL, Zhang JG, Sutherland RM, Anstee NS, et al. Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death Differ. 2017;24:878\u201388.","journal-title":"Cell Death Differ"},{"key":"4285_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/1074-7613(95)90161-2","volume":"3","author":"LH Boise","year":"1995","unstructured":"Boise LH, Minn AJ, Noel PJ, June CH, Accavitti MA, Lindsten T, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995;3:87\u201398.","journal-title":"Immunity"},{"key":"4285_CR25","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nature02067","volume":"426","author":"JT Opferman","year":"2003","unstructured":"Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426:671\u20136.","journal-title":"Nature"},{"key":"4285_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/sj.onc.1202049","volume":"17","author":"J Gomez","year":"1998","unstructured":"Gomez J, Martinez AC, Gonzalez A, Garcia A, Rebollo A. The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT. Oncogene. 1998;17:1235\u201343.","journal-title":"Oncogene"},{"key":"4285_CR27","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.4049\/jimmunol.161.9.4627","volume":"161","author":"JD Lord","year":"1998","unstructured":"Lord JD, McIntosh BC, Greenberg PD, Nelson BH. The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J Immunol. 1998;161:4627\u201333.","journal-title":"J Immunol"},{"key":"4285_CR28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/icb.2017.72","volume":"95","author":"EM Carrington","year":"2017","unstructured":"Carrington EM, Tarlinton DM, Gray DH, Huntington ND, Zhan Y, Lew AM. The life and death of immune cell types: the role of BCL-2 anti-apoptotic molecules. Immunol Cell Biol. 2017;95:870\u20137.","journal-title":"Immunol Cell Biol"},{"key":"4285_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.coi.2007.05.005","volume":"19","author":"D Hildeman","year":"2007","unstructured":"Hildeman D, Jorgensen T, Kappler J, Marrack P. Apoptosis and the homeostatic control of immune responses. Curr Opin Immunol. 2007;19:516\u201321.","journal-title":"Curr Opin Immunol"},{"key":"4285_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.9","volume":"3","author":"X Wang","year":"2012","unstructured":"Wang X, Szymczak-Workman AL, Gravano DM, Workman CJ, Green DR, Vignali DA. Preferential control of induced regulatory T cell homeostasis via a Bim\/Bcl-2 axis. Cell Death Dis. 2012;3:e270.","journal-title":"Cell Death Dis"},{"key":"4285_CR31","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1084\/jem.182.6.1973","volume":"182","author":"DA Grillot","year":"1995","unstructured":"Grillot DA, Merino R, Nunez G. Bcl-XL displays restricted distribution during T cell development and inhibits multiple forms of apoptosis but not clonal deletion in transgenic mice. J Exp Med. 1995;182:1973\u201383.","journal-title":"J Exp Med"},{"key":"4285_CR32","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1158\/2159-8290.CD-14-0353","volume":"4","author":"TN Chonghaile","year":"2014","unstructured":"Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014;4:1074\u201387.","journal-title":"Cancer Discov"},{"key":"4285_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/gt.2010.59","volume":"17","author":"P Neeson","year":"2010","unstructured":"Neeson P, Shin A, Tainton KM, Guru P, Prince HM, Harrison SJ, et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther. 2010;17:1105\u201316.","journal-title":"Gene Ther"},{"key":"4285_CR34","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","volume":"123","author":"Y Xu","year":"2014","unstructured":"Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood. 2014;123:3750\u20139.","journal-title":"Blood"},{"key":"4285_CR35","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00262-011-0977-7","volume":"60","author":"S Yang","year":"2011","unstructured":"Yang S, Gattinoni L, Liu F, Ji Y, Yu Z, Restifo NP, et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol Immunother. 2011;60:739\u201349.","journal-title":"Cancer Immunol Immunother"},{"key":"4285_CR36","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.bbmt.2004.08.003","volume":"10","author":"JJ Auletta","year":"2004","unstructured":"Auletta JJ, Devecchio JL, Ferrara JL, Heinzel FP. Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation. Biol Blood Marrow Transpl. 2004;10:834\u201347.","journal-title":"Biol Blood Marrow Transpl"},{"key":"4285_CR37","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.bmt.1704953","volume":"35","author":"DL Porter","year":"2005","unstructured":"Porter DL, June CH. T-cell reconstitution and expansion after hematopoietic stem cell transplantation: \u2018T\u2019 it up! Bone Marrow Transpl. 2005;35:935\u201342.","journal-title":"Bone Marrow Transpl"},{"key":"4285_CR38","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1242\/jcs.090514","volume":"125","author":"L Happo","year":"2012","unstructured":"Happo L, Strasser A, Cory S. BH3-only proteins in apoptosis at a glance. J Cell Sci. 2012;125:1081\u20137.","journal-title":"J Cell Sci"},{"key":"4285_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/nri1568","volume":"5","author":"A Strasser","year":"2005","unstructured":"Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol. 2005;5:189\u2013200.","journal-title":"Nat Rev Immunol"},{"key":"4285_CR40","doi-asserted-by":"publisher","first-page":"10967","DOI":"10.1073\/pnas.1005256107","volume":"107","author":"EM Carrington","year":"2010","unstructured":"Carrington EM, Vikstrom IB, Light A, Sutherland RM, Londrigan SL, Mason KD, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA. 2010;107:10967\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4285_CR41","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1083\/jcb.200905153","volume":"186","author":"D Merino","year":"2009","unstructured":"Merino D, Giam M, Hughes PD, Siggs OM, Heger K, O\u2019Reilly LA, et al. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol. 2009;186:355\u201362.","journal-title":"J Cell Biol"},{"key":"4285_CR42","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","volume":"8","author":"S Caenepeel","year":"2018","unstructured":"Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective mcl1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies. Cancer Discov. 2018;8:1582\u201397.","journal-title":"Cancer Discov"},{"key":"4285_CR43","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.18632\/oncotarget.27262","volume":"10","author":"A Hadji","year":"2019","unstructured":"Hadji A, Schmitt GK, Schnorenberg MR, Roach L, Hickey CM, Leak LB, et al. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide. Oncotarget. 2019;10:6219\u201333.","journal-title":"Oncotarget"},{"key":"4285_CR44","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","volume":"538","author":"A Kotschy","year":"2016","unstructured":"Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538:477\u201382.","journal-title":"Nature"},{"key":"4285_CR45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ni.2649","volume":"14","author":"W Pierson","year":"2013","unstructured":"Pierson W, Cauwe B, Policheni A, Schlenner SM, Franckaert D, Berges J, et al. Antiapoptotic Mcl-1 is critical for the survival and niche-filling capacity of Foxp3(+) regulatory T cells. Nat Immunol. 2013;14:959\u201365.","journal-title":"Nat Immunol"},{"key":"4285_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2012.38","volume":"3","author":"PE Cippa","year":"2012","unstructured":"Cippa PE, Kraus AK, Lindenmeyer MT, Chen J, Guimezanes A, Bardwell PD, et al. Resistance to ABT-737 in activated T lymphocytes: molecular mechanisms and reversibility by inhibition of the calcineurin-NFAT pathway. Cell Death Dis. 2012;3:e299.","journal-title":"Cell Death Dis"},{"key":"4285_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms2719","volume":"4","author":"P Koenen","year":"2013","unstructured":"Koenen P, Heinzel S, Carrington EM, Happo L, Alexander WS, Zhang JG, et al. Mutually exclusive regulation of T cell survival by IL-7R and antigen receptor-induced signals. Nat Commun. 2013;4:1735.","journal-title":"Nat Commun"},{"key":"4285_CR48","doi-asserted-by":"publisher","first-page":"5729","DOI":"10.4049\/jimmunol.1100102","volume":"186","author":"S Kurtulus","year":"2011","unstructured":"Kurtulus S, Tripathi P, Moreno-Fernandez ME, Sholl A, Katz JD, Grimes HL, et al. Bcl-2 allows effector and memory CD8+ T cells to tolerate higher expression of Bim. J Immunol. 2011;186:5729\u201337.","journal-title":"J Immunol"},{"key":"4285_CR49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/cdd.2013.25","volume":"20","author":"P Tripathi","year":"2013","unstructured":"Tripathi P, Koss B, Opferman JT, Hildeman DA. Mcl-1 antagonizes Bax\/Bak to promote effector CD4(+) and CD8(+) T-cell responses. Cell Death Differ. 2013;20:998\u20131007.","journal-title":"Cell Death Differ"},{"key":"4285_CR50","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.4049\/jimmunol.178.7.4027","volume":"178","author":"P Tripathi","year":"2007","unstructured":"Tripathi P, Mitchell TC, Finkelman F, Hildeman DA. Cutting edge: limiting amounts of IL-7 do not control contraction of CD4+ T cell responses. J Immunol. 2007;178:4027\u201331.","journal-title":"J Immunol"},{"key":"4285_CR51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/sj.cdd.4401265","volume":"10","author":"C Verschelde","year":"2003","unstructured":"Verschelde C, Walzer T, Galia P, Biemont MC, Quemeneur L, Revillard JP, et al. A1\/Bfl-1 expression is restricted to TCR engagement in T lymphocytes. Cell Death Differ. 2003;10:1059\u201367.","journal-title":"Cell Death Differ"},{"key":"4285_CR52","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.immuni.2010.06.005","volume":"32","author":"FM Wensveen","year":"2010","unstructured":"Wensveen FM, van Gisbergen KP, Derks IA, Gerlach C, Schumacher TN, van Lier RA, et al. Apoptosis threshold set by Noxa and Mcl-1 after T cell activation regulates competitive selection of high-affinity clones. Immunity. 2010;32:754\u201365.","journal-title":"Immunity"},{"key":"4285_CR53","doi-asserted-by":"publisher","first-page":"521","DOI":"10.4049\/jimmunol.181.1.521","volume":"181","author":"I Dzhagalov","year":"2008","unstructured":"Dzhagalov I, Dunkle A, He YW. The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J Immunol. 2008;181:521\u20138.","journal-title":"J Immunol"},{"key":"4285_CR54","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"4285_CR55","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.beha.2019.05.008","volume":"32","author":"VA Guerra","year":"2019","unstructured":"Guerra VA, DiNardo C, Konopleva M. Venetoclax-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32:145\u201353.","journal-title":"Best Pract Res Clin Haematol"},{"key":"4285_CR56","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. New Engl J Med. 2019;380:2095\u2013103.","journal-title":"New Engl J Med"},{"key":"4285_CR57","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","volume":"6","author":"M Konopleva","year":"2016","unstructured":"Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6:1106\u201317.","journal-title":"Cancer Discov"},{"key":"4285_CR58","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/bjh.16268","volume":"188","author":"R Shahswar","year":"2020","unstructured":"Shahswar R, Beutel G, Klement P, Rehberg A, Gabdoulline R, Koenecke C, et al. FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed\/refractory acute leukaemia. Br J Haematol. 2020;188:e11\u2013e15.","journal-title":"Br J Haematol"},{"key":"4285_CR59","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21:66.","journal-title":"Curr Treat Options Oncol"},{"key":"4285_CR60","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"4285_CR61","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/cancers11071037","volume":"11","author":"V Atsaves","year":"2019","unstructured":"Atsaves V, Leventaki V, Rassidakis GZ, Claret FX. AP-1 transcription factors as regulators of immune responses in cancer. Cancers. 2019;11:1037.","journal-title":"Cancers"},{"key":"4285_CR62","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/32100","volume":"392","author":"L Chen","year":"1998","unstructured":"Chen L, Glover JN, Hogan PG, Rao A, Harrison SC. Structure of the DNA-binding domains from NFAT, Fos and Jun bound specifically to DNA. Nature. 1998;392:42\u201348.","journal-title":"Nature"},{"key":"4285_CR63","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1146\/annurev.immunol.15.1.707","volume":"15","author":"A Rao","year":"1997","unstructured":"Rao A, Luo C, Hogan PG. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol. 1997;15:707\u201347.","journal-title":"Annu Rev Immunol"},{"key":"4285_CR64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41590-020-00818-9","volume":"22","author":"V Verma","year":"2021","unstructured":"Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, et al. MEK inhibition reprograms CD8(+) T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021;22:53\u201366.","journal-title":"Nat Immunol"},{"key":"4285_CR65","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1038\/onc.2008.26","volume":"27","author":"SL Peng","year":"2008","unstructured":"Peng SL. Foxo in the immune system. Oncogene. 2008;27:2337\u201344.","journal-title":"Oncogene"},{"key":"4285_CR66","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.4049\/jimmunol.168.10.5024","volume":"168","author":"M Stahl","year":"2002","unstructured":"Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM, et al. The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol. 2002;168:5024\u201331.","journal-title":"J Immunol"},{"key":"4285_CR67","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ccell.2019.04.005","volume":"35","author":"X Zhao","year":"2019","unstructured":"Zhao X, Ren Y, Lawlor M, Shah BD, Park PMC, Lwin T, et al. BCL2 amplicon loss and transcriptional remodeling drives ABT-199 resistance in b cell lymphoma models. Cancer Cell. 2019;35:752\u2013766 e759.","journal-title":"Cancer Cell"},{"key":"4285_CR68","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.4049\/jimmunol.0900592","volume":"183","author":"P Agarwal","year":"2009","unstructured":"Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory. J Immunol. 2009;183:1695\u2013704.","journal-title":"J Immunol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04285-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04285-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T01:06:28Z","timestamp":1675818388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-021-04285-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,27]]},"references-count":68,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["4285"],"URL":"https:\/\/doi.org\/10.1038\/s41419-021-04285-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,27]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were approved by and performed in accordance with the guidelines and regulations set forth by the Institutional Animal Care and Use Committee of the University of Chicago. This study did not involve human subjects, data, or tissue.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing financial interests. JLL received research funding from a combined AbbVie-University of Chicago research collaboration. BRB receives remuneration as an advisor to Magenta Therapeutics and BlueRock Therapeutics, research funding from BlueRock Therapeutics, Rheos Medicines, Childrens\u2019 Cancer Research Fund, and KidsFirst Fund, and is a co-founder of Tmunity. JDL is an employee of AbbVie Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1005"}}